Organisation paid for research Program year 2025 Source: CMS Open Payments

New Jersey Heart

Neither a doctor nor a teaching hospital

Research payments

$740,086

18 payments

Through program year 2025, New Jersey Heart is reported as receiving $740,086 in research payments, across 18 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$90,764	4
2024	Research	$113,036	3
2023	Research	$158,598	5
2022	Research	$337,850	2
2021	Research	$3,223	2
2020	Research	$10,300	1
2019	Research	$26,315	1

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $740,086 18 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An Inclisiran First Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/D $296,526 1 payment
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $135,419 3 payments
A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE) $135,020 4 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $133,283 6 payments
Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction $36,615 2 payments
A 52 Week Open Label Evaluation of the Effects of Sacubitril Valsartan Lcz696 Therapy on Biomarkers Myocardial Remodeling and Patient Reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction $2,898 1 payment
A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An ""Inclisiran First"" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/DL) Despite Receiving Maximally Tolerated Statin Therapy (Victorion-Initiate) $325 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.